Skip to main content
Premium Trial:

Request an Annual Quote

GE Healthcare Obtains License for c-Met Peptides from Dyax

NEW YORK (GenomeWeb News) – Dyax is granting GE Healthcare rights to develop and commercialize c-Met imaging peptides for potential use in patient selection under a deal announced today.

Under the terms of the deal, GE will pay biopharmaceutical firm Dyax upfront, milestone, and royalty payments. Further terms were not disclosed.

GE said it plans to explore with academic and pharmaceutical collaborators use of the peptides for diagnostic applications as well as for selection of patients for cancer research. The license being granted also includes application of the peptides in positron emission tomography, single proton emission computed tomography, and optical imaging.

"As in vivo imaging technologies become increasingly important in oncology drug development, our vision is that we will be able to rapidly develop new targeted molecular diagnostics — not just for our own clinical portfolio, but as companion diagnostic offerings for our strategic biopharmaceutical partnerships," Marivi Mendizabal, head of research, GE Healthcare Medical Diagnostics, said in a statement.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.